Apple announces iPhone 17 with 48MP cameras and 6.3-inch display
Investing.com - Bernstein has reiterated an Outperform rating on Coloplast A/S (CSE:COLOB) with a price target of DKK790.00.
The stock rose 2% following the company’s Capital Markets Day (CMD), suggesting investors had modest expectations heading into the event.
While Coloplast’s guidance came in below Bernstein’s estimates, it exceeded consensus forecasts, according to the research firm.
Bernstein described Coloplast as "one of the highest quality Medtech companies globally," highlighting its attractive end-market exposure with high recurring revenues in Chronic Care and mid to high single-digit growth across most categories.
The firm noted Coloplast’s dominant market share positions make it "exceptionally well placed" to outgrow peers through volume gains and product innovation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.